COMMUNIQUÉS West-GlobeNewswire

Medicus Pharma Receives Positive FDA Feedback and Central IRB Approval for Optimized Phase 2 Teverelix® Novel Study in Acute Urinary Retention
16/07/2026
Regulatory and ethical-review milestones advance a capital-efficient Phase 2 study expected to enroll ~126 patients versus ~390 under the previously disclosed development plan PHILADELPHIA, July 16, 2026 (GLOBE NEWSWIRE [...]
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
16/07/2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial results on Wednesday, [...]
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
16/07/2026
BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report [...]
CDT Equity Inc. Announces Reverse Stock Split
16/07/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, July 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), announces that its board of directors has approved a 1-for-10 reverse stock split of [...]
SRX Global Regains Full Compliance with NYSE American Listing Standards
16/07/2026
Company Resolves Section 1003(a)(i) and (ii) Deficiencies; Compliance Indicator to Be Removed NORTH PALM BEACH, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the "Company", or "SRX"), an [...]
BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness
16/07/2026
Following the XcellaraHeart™ announcement, the Company outlines its broader development model, pairing a clinically studied mobilization base with a planned series of targeted signaling formulas LAS VEGAS, July 16, 2026 [...]
BienRaíz Launches 240 mg Magnesium Glycinate Supplement, Expanding Its Daily Wellness Portfolio with Targeted Mineral Support
16/07/2026
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- BienRaíz today announced the launch of BienRaíz Magnesium Glycinate Supplement, a daily magnesium glycinate supplement formulated with 240 mg elemental magnesium per serving. [...]
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
16/07/2026
Sales Highlights (unaudited): Global FY26 sales AUD$7.7 million up 6% on prior comparative period (pcp) 2H FY26 sales AUD$3.5 million up 7% on pcp 4Q FY26 sales AUD$2.0 million up 2% on pcp Australia FY26 sales AUD$5.8 [...]
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
16/07/2026
www.arlettapharmasolutions.com FDA endorses key elements of the proposed Phase 2 dose-ranging study and openness to a single pivotal Phase 3 study to support a future NDA Amsterdam, the Netherlands, 16 July 2026 — [...]
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16/07/2026
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, [...]
4TEEN4 Receives U.S. FDA Fast Track Designation for Invobenitug in Cardiogenic Shock
16/07/2026
Hennigsdorf/Berlin, July 16, 2026 – 4TEEN4 Pharmaceuticals GmbH today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to invobenitug (formerly known as procizumab), for the [...]
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
16/07/2026
First-in-class clustering agonist antibody DIAG723 is designed to restore ALK1 signaling, the genetically disrupted pathway that causes abnormal vascular development, bleeding, and arteriovenous malformations (AVMs) in [...]
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
16/07/2026
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst’s [...]
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
16/07/2026
Boehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701, in people living with obesity and overweight. 1 BI 3034701 is a [...]
Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30
16/07/2026
Leiden, the Netherlands, July 16, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and [...]
argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
16/07/2026
July 16, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Curaechoice and Symbol Health Solutions Partner to Transform Employer Healthcare with Integrated Onsite Care and Nationwide No-Cost Access
16/07/2026
Strategic partnership combines trusted onsite care with nationwide no-cost healthcare access, making employee healthcare simpler, more connected, and more affordable. Birmingham, Alabama, July 15, 2026 (GLOBE NEWSWIRE [...]
ARCPOINT ANTICIPATES DELAY IN FILING ANNUAL FINANCIAL STATEMENTS
16/07/2026
GREENVILLE, South Carolina, July 15, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the " Company " or “ ARCpoint ”) announces that it will likely miss its filing deadline of July 29, 2026 (the “ Annual Filing [...]
Neutrolis Announces New England Journal of Medicine Publication Demonstrating First Clinical Evidence for NET-Degrading Therapy in Severe, Treatment-Refractory Systemic Lupus Erythematosus (SLE) Caused by DNASE1L3 Deficiency
15/07/2026
Treatment with investigational DNASE1L3 analog NTR-441, which degrades neutrophil extracellular traps (NETs), resulted in rapid clinical improvement in a patient with treatment-refractory SLE Results provide first human [...]

Pages